CONTENTS:
- Clarifying 'safer supply' to enrich policy discussions [Editorial]. Kilmer B., Pardo B., p. 994-997.
- How should policymakers regulate the tetrahydrocannabinol content of cannabis products in a legal market? [Addiction opinion and debate]. Hall W., Leung J., Carlini B.H., p. 998-1003.
- The virtues of bans on high-THC content cannabis products? Caulkins J.P., p. 1004-1005.
- Strictly regulated cannabis retail models with state control can provide lessons in how jurisdictions can regulate THC. Pardal M., Wadsworth E., p. 1005-1007.
- Using the standard THC unit to regulate THC content in legal cannabis markets. Freeman T.P., Lorenzetti V., p. 1007-1009.
- Do not let the ideal be the enemy of good enough regulation. Hall W., Leung J., Carlini B.H., p. 1009-1010.
- Delta-8 tetrahydrocannabinol: a scoping review and commentary. LoParco C.R., Rossheim M.E., Walters S.T., Zhou Z., Olsson S., Sussman S.Y., p. 1011-1028.
- Comparative efficacy of psychosocial interventions for opioid-dependent people receiving methadone maintenance treatment: A network meta-analysis. Wen H., Xiang X., Jiang Y., Zhang H., Zhang P., Chen R., et al., p. 1029-1039.
- An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial. Votaw V.R., Witkiewitz K., Van Horn M.L., Crist R.C., Pond T., Kranzler H.R., p. 1040-1052.
- Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers. Jangard S., Jayaram-Lindström N., Isacsson N.H., Matheson G.J., Plavén-Sigray P., Franck J., et al., p. 1053-1061.
- The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration. Perumalswami P.V., Kilpatrick S., Frost M.C., Adams M.A., Kim H.M., Zhang L., et al., p. 1062-1071.
- Understanding the differential effect of local socio-economic conditions on the relation between prescription opioid supply and drug overdose deaths in US counties. Fink D.S., Keyes K.M., Branas C., Cerdá M., Gruenwald P., Hasin D., p. 1072-1082.
- Directional associations between cannabis use and depression from late adolescence to young adulthood: the role of adverse childhood experiences. Davis J.P., Pedersen E.R., Tucker J.S., Prindle J., Dunbar M.S., Rodriguez A., et al., p. 1083-1092.
- Obstetric pain management for pregnant women with opioid use disorder: A qualitative and quantitative comparison of patient and provider perspectives (QUEST study). Nowakowski E., Dayananda S., Morgan M., Jarvis O., Altamirano V., LaSorda K.R., et al., p. 1093-1104.
- Commentary on Nowakowski et al.: Bringing the participants' own words into addictions research-a win-win for patients and investigators. Martin C.E., p. 1105-1106.
- The predictive validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for moderate- to high-risk cannabis, methamphetamine and opioid use after release from prison. Cumming C., Kinner S.A., McKetin R., Young J.T., Li I., Preen D.B., p. 1107-1115.
- Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis C virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials. van Santen D.K., Lodi S., Dietze P., van den Boom W., Hayashi K., Dong H., et al., p. 1116-1126.
- The relationship between problematic gambling severity and engagement with gambling products: Longitudinal analysis of the Emerging Adults Gambling Survey. Wardle H., Tipping S., p. 1127-1139.
- Effectiveness and cost-effectiveness of behavioural support for prolonged abstinence for smokers wishing to reduce but not quit: Randomised controlled trial of physical activity assisted reduction of smoking (TARS). Taylor A.H., Thompson T.P., Streeter A., Chynoweth J., Snowsill T., Ingram W., et al., p. 1140-1152.
- Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework. Lafferty L., Sheehan Y., Cochrane A., Grebely J., Lloyd A.R., Treloar C., p. 1153-1160.
- E-cigarette cessation and transitions in combusted tobacco smoking status: longitudinal findings from the US FDA PATH Study. Klemperer E.M., Bunn J.Y., Palmer A.M., Smith T.T., Toll B.A., Cummings K.M., et al., p. 1161-1166.
- Outcome class imbalance and rare events: An underappreciated complication for overdose risk prediction modeling. Cartus A.R., Samuels E.A., Cerdá M., Marshall B.D.L., p. 1167-1176.
- Changes in HIV incidence in people who inject drugs in Ireland from 2000 to 2018: longitudinal observational study. McCarron P., Smyth B.P., p. 1177-1181.
- Addiction Lives: Robin Davidson. Berridge V., p. 1182-1183.
- A critique of the Australian National Health and Medical Research Council CEO statement on electronic cigarettes. Mendelsohn C.P., Hall W., Borland R., Wodak A., Beaglehole R., Benowitz N.L., et al., p. 1184-1192.